15 completed, 4 active not recruiting, 4 terminated, 3 recruiting. 22 Phase 2, 4 Phase 3, 3 Phase 1, 1 Not applicable.
Follow Sarcoma Alliance for Research through Collaboration: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma nab-Sirolimus - Epithelioid Hemangioendothelioma (EHE) | Phase 2 | Recruiting | Sarcoma Alliance for Research through Collaboration | 41 | 2026-02-24 | 2026-05-26 |
| A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma Physician's Choice, Tebentafusp - HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS) | Phase 2 | Recruiting | Sarcoma Alliance for Research through Collaboration | 47 | 2025-10-22 | 2026-10-02 |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Bezuclastinib in combination with sunitinib - Gastrointestinal Stromal Tumors, GIST | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 40 | 2024-08-01 | 2025-10-31 |
| SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma Abemaciclib, Placebo - Advanced Dedifferentiated Liposarcoma | Phase 3 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 108 | 2021-11-11 | 2026-10-05 |
| SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma Regorafenib 40 MG, Regorafenib 20MG, Nivolumab - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 48 | 2021-06-04 | 2025-10-31 |
| SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy - Ewing Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 37 | 2021-01-05 | 2025-12-17 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity Pembrolizumab - Soft Tissue Sarcoma of the Extremity | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 126 | 2017-07-19 | 2023-11-18 |
| SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) Pazopanib, Trametinib - Gastrointestinal Stromal Tumors | Phase 2 | Withdrawn | Sarcoma Alliance for Research through Collaboration | 2017-01-01 | 2017-10-12 | |
| Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort Conventional Surgery, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis - Recurrent Adult Soft Tissue Sarcoma | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 51 | 2016-02-03 | 2026-03-10 |
| SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Mocetinostat, Gemcitabine - Metastatic Leiomyosarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2015-11-12 | 2019-01-29 |
| SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Pembrolizumab - Soft Tissue Sarcoma, Bone Sarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 144 | 2015-03-01 | 2020-09-29 |
| SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Regorafenib, Placebo - Liposarcoma, Osteogenic Sarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 131 | 2014-07-01 | 2023-11-07 |
| ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma niraparib, Temozolomide, Irinotecan - Ewing Sarcoma | Phase 1 | Completed | Sarcoma Alliance for Research through Collaboration | 34 | 2014-05-01 | 2021-01-12 |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) ganetespib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2013-12-01 | 2019-05-15 |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors everolimus, bevacizumab - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 25 | 2012-09-01 | 2019-03-06 |
| A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302 in Combination with Doxorubicin, Doxorubicin - Soft Tissue Sarcoma | Phase 3 | Completed | Threshold Pharmaceuticals | 640 | 2011-09-01 | 2016-06-02 |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 133 | 2011-05-01 | 2014-08-08 |
| Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients Imatinib mesylate - Gastrointestinal Stromal Tumors | Phase 3 | Terminated | Sarcoma Alliance for Research through Collaboration | 5 | 2010-01-01 | 2013-09-09 |
| A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung Saracatinib, Placebo - Osteosarcoma | Phase 2 | Terminated | Sarcoma Alliance for Research through Collaboration | 38 | 2009-03-01 | 2020-01-18 |
Showing 20 of 28. Sign in to see all of them.
Sarcoma (13) · Neurofibrosarcoma (6) · Gastrointestinal Stromal Tumors (4) · Osteosarcoma (4) · Chondrosarcoma (3) · Leiomyosarcoma (3) · Sarcoma, Alveolar Soft Part (3) · Sarcoma, Ewing (3) · Neurofibromatosis 1 (2) · Recurrence (2) · Rhabdomyosarcoma (2) · Bone Neoplasms (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Chondrosarcoma, Mesenchymal (1) · Chordoma (1)
Doxorubicin (4) · Gemcitabine (3) · Docetaxel (2) · Filgrastim (2) · Imatinib Mesylate (2) · Irinotecan (2) · Sirolimus (2) · TH 302 (2) · Trabectedin (2) · pembrolizumab (2) · regorafenib (2) · AZD 6244 (1) · Allopurinol (1) · Antiemetics (1) · Bevacizumab (1)
United States (24) · United Kingdom (4) · Canada (3) · France (3) · Germany (3) · Italy (3) · Spain (3) · Australia (2) · Austria (2) · Belgium (2) · Denmark (2) · Hungary (2) · Netherlands (2) · Poland (2) · Israel (1)
AeRang Kim, MD, PhD (2) · Brigitte C. Widemann, MD (2) · Brigitte Widemann, MD (2) · Scott Schuetze, MD, PhD (2) · Andrew Wagner, MD, PhD (1) · Anusa Kalbasi, MD (1) · Candace Haddox, MD (1) · David Kirsch, MD, PhD (1) · Dejka Araujo, MD (1) · Edwin Choy, MD, PhD (1) · Elizabeth Fox, MD (1) · Hussein Tawbi, MD, PhD (1) · James E. Butrynski, MD (1) · John Glod, MD/PhD (1)
PMID 20489620, PMID 21140148, PMID 22025149, PMID 22363068, PMID 22682017, PMID 23335221, PMID 25185097, PMID 28651927, PMID 28988646, PMID 31013172, PMID 31401903, PMID 32089640, PMID 32701199, PMID 33289920, PMID 39547252, PMID 41405883, PMID 41991689
2009 (1), U01CA236220 (1)